Silver Book Fact

Fact image

The present value QUALY gains associated with a new drug that by 2010 could delay disease onset by 1, 3, and 5 years. The dollar value estimates range from approximately $0.7 trillion, for a 1 year delay in Alzheimer’s disease onset for all new cases from 2010 to 2050 (QUALY valued at $100,000), to almost $4 trillion, for a 5-year delay in Alzheimer’s disease onset for all new cases between 2010 and 2050 (QUALY valued at $175,000).

Vernon, John, Robert Goldberg, Yashodhara Dash, and Guruprasaadh Muralimohan. Alzheimer’s Disease and Cost-effectiveness Analyses: Ensuring good value for money?. Working Paper — Pending Publication; 2007. http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=12477

Reference

Title
Alzheimer’s Disease and Cost-effectiveness Analyses: Ensuring good value for money?
Publisher
Working Paper — Pending Publication
Publication Date
2007
Authors
Vernon, John, Robert Goldberg, Yashodhara Dash, and Guruprasaadh Muralimohan
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Delaying the onset of Alzheimer’s by only 5 years could reduce the number of people with Alzheimer’s by almost 50% after 50 years.  
  • Medicare Costs, Slowed Progression  
  • A treatment breakthrough that slowed the progression of Alzheimer’s disease would reduce the number of people with the disease from 2.4 million to 1.1 million in 2020, and from 6.5…  
  • Impact of Slowed Progression on Alzheimer’s Disease Growth, Americans Age 65 and Older with Alzheimer’s, 2010-2050  
  • An Alzheimer’s disease research study showed that billions of dollars could be saved if physicians could intervene before someone becomes symptomatic. This positive net savings occurred with both drug treatment…